Cargando…

New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases

Type 2 diabetes is a risk factor for Alzheimer's disease and Parkinson's disease. Insulin signaling in the brains of people with Alzheimer's disease or Parkinson's disease is impaired. Preclinical studies of growth factors showed impressive neuroprotective effects. In animal mode...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hölscher, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281420/ https://www.ncbi.nlm.nih.gov/pubmed/25558231 http://dx.doi.org/10.4103/1673-5374.145342

Ejemplares similares

On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
por: Segura-Aguilar, Juan
Publicado: (2017)

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review
por: Reich, Niklas, et al.
Publicado: (2022)

TFP5/TP5 peptide provides neuroprotection in the MPTP model of Parkinson's disease
por: Binukumar, BK, et al.
Publicado: (2016)

Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases
por: Freyssin, Aline, et al.
Publicado: (2018)

Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy
por: Sampaio, Tuane Bazanella, et al.
Publicado: (2017)

Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery
por: Colón, Jennifer M., et al.
Publicado: (2016)

Drug repurposing strategies of relevance for Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2021)

Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification
por: Lauterbach, Edward C.
Publicado: (2016)

Neuroprotection and antioxidants
por: Lalkovičová, Maria, et al.
Publicado: (2016)

Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor
por: Hernández, Carolina Castillo, et al.
Publicado: (2017)

Neuroinflammation in Parkinson’s Disease and its Treatment Opportunities
por: Çınar, Elif, et al.
Publicado: (2022)

Tamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injury
por: Salgado, Iris K., et al.
Publicado: (2015)

Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke
por: Lee, Jin Hwan, et al.
Publicado: (2017)

Neuroprotective effects of D-Ala(2)GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model
por: Faivre, Emilie, et al.
Publicado: (2013)

Young blood products: emerging treatment for Alzheimer's disease?
por: Khoury, Rita, et al.
Publicado: (2018)

The treatment of Parkinson's disease with deep brain stimulation: current issues
por: Moldovan, Alexia-Sabine, et al.
Publicado: (2015)

Neuroprotective effects of statins against amyloid β-induced neurotoxicity
por: Li, Hsin-Hua, et al.
Publicado: (2018)

Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson’s Disease
por: Ferreira, Carla, et al.
Publicado: (2020)

Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
por: Fisher, Robert A., et al.
Publicado: (2022)

Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy
por: Bruna, Jordi, et al.
Publicado: (2018)

TRPV1 may increase the effectiveness of estrogen therapy on neuroprotection and neuroregeneration
por: Ramírez-Barrantes, Ricardo, et al.
Publicado: (2016)

A new direction for Alzheimer's research
por: Weinstein, James D.
Publicado: (2018)

Patient-specific pluripotent stem cell-based Parkinson’s disease models showing endogenous alpha-synuclein aggregation
por: Oh, Yohan
Publicado: (2019)

Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson's and Alzheimer's Diseases as Disease Modifying Agents
por: Youdim, Moussa B. H.
Publicado: (2010)

Heterocyclic compounds as key structures for the interaction with old and new targets in Alzheimer’s disease therapy
por: Hiremathad, Asha, et al.
Publicado: (2017)

Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
por: Reich, Niklas, et al.
Publicado: (2020)

Chronic neuroprotective effects of low concentration lithium on SH-SY5Y cells: possible involvement of stress proteins and gene expression
por: Nciri, Riadh, et al.
Publicado: (2014)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

Neural grafting for Parkinson's disease: challenges and prospects
por: Stoker, Thomas B., et al.
Publicado: (2017)

Uncoupling protein 2 in the glial response to stress: implications for neuroprotection
por: Hass, Daniel T., et al.
Publicado: (2016)

Neuroprotective Effects of Quercetin in Alzheimer’s Disease
por: Khan, Haroon, et al.
Publicado: (2019)

Neuroprotective Effect of Caffeine in Alzheimer’s Disease
por: M Yelanchezian, Y Mukish, et al.
Publicado: (2022)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

MicroRNAs in Parkinson's disease and emerging therapeutic targets
por: Martinez, Bridget, et al.
Publicado: (2017)

The emerging role of autophagic-lysosomal dysfunction in Gaucher disease and Parkinson's disease
por: Kinghorn, Kerri J., et al.
Publicado: (2017)

Systems analysis shows that thermodynamic physiological and pharmacological fundamentals drive COVID‐19 and response to treatment
por: Head, Richard J., et al.
Publicado: (2022)

ΔN-Bcl-xL, a therapeutic target for neuroprotection
por: Park, Han-A, et al.
Publicado: (2017)

New Drug Discovery Paradigms for Retinal Diseases: A Focus on Retinal Organoids
por: Aasen, Davis M., et al.
Publicado: (2020)

Alzheimer's disease: the silver tsunami of the 21(st) century
por: Sarkar, Ankita, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0dbdhhkoqq1cmtaafqsig5q389